Skip to main content
. 2015 Oct 3;6(34):35813–35829. doi: 10.18632/oncotarget.5358

Figure 5. Effect of CTHRC1 gain/loss of function on EOC cell malignant phenotype.

Figure 5

A. Down-regulation and up-regulation of CTHRC1 by CTHRC1-siRNA and pcDNA3.1-CTHRC1, respectively. Data are means ± SD of 3 independent experiments (**p < 0.01). B. 48 h after transfection, cells were seeded in the null-adhesion condition (day 0). At days 2–3, an adhesion index (%) was calculated as [n cells grown in adhesion/(n cells grown in adhesion + n cells grown in suspension) × 100%]. CTHRC1 significantly inhibited EOC cell adhesion (*p < 0.05). C. Transwell assay showed that cell invasiveness was diminished by CTHRC1-siRNA treatment, and enhanced by pcDNA3.1-CTHRC1 treatment (*p < 0.05). D. Transfected EOC cells were also tested for the ability to form colonies in soft agar: 7 days after seeding in soft agar, transfected cell samples were analyzed by light microscopy and the size/number of colonies was evaluated, considering percentage fractions. E. Cell viability was tested by MTT assay: cell viability was impaired by CTHRC1-siRNA treatment (the upper), and elevated by pcDNA3.1-CTHRC1 treatment (the lower). Data are from three separate experiments (*p < 0.05).